TFF Pharmaceuticals Announces Phase 1 Clinical Trial Progress for Voriconazole Inhalation Powder to Treat Invasive Pulmonary Aspergillosis (IPA)

~ Successfully completes single ascending dose phase of first clinical study in healthy subjects for a direct-to-lung, Thin Film Freezing (TFF) dry-powder formulation ~ Invasive Pulmonary Aspergillosis is a severe fungal pulmonary disease with a mortality rate that can reach 90 percent¹ in some patient populations

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here